ESTRO 2024 - Abstract Book

S2264

Clinical - Upper GI

ESTRO 2024

Conclusion:

Our patient base was similar to CtE: e.g. (ours vs CtE) PS=0, 27 vs 31%; PS=1, 54 vs 55%; Median age 71 vs 72 years. Our OS figures are similar to CtE’s: 1 year OS 76.5% (95% CI: 62.4 to 85.9%); 2 year OS 41.7% (95% CI: 22.4 to 60.0%) and to a large Canadian/USA cohort 1-year OS 77.4% (5). This is reassuring that outcomes for a novel radiotherapy technology, initially commissioned through a limited number of centres, are replicable when broader national commissioning occurs.

Keywords: Hepatocellular Carcinoma, SBRT, Outcomes

References:

1. Matsuo Y. Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview. Curr. Oncol. 2023;30:2493.

2. NHS. Clinical Commissioning Policy Stereotactic Ablative Radiotherapy (SABR) for Hepatocellular Carcinoma (Adults) (URN: 1913) [200206P].

3. KiTEC. Commissioning through Evaluation: Stereotactic ablative body radiotherapy (SABR) for patients with hepatocellular carcinoma report. 2019.

4. Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: The Model for End-stage Liver Disease Updated for the Modern Era. Gastroenterology. 2021;161:1887.

5. Mathew AS, Atenafu EG, Owen D, et al. Long term outcomes of Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Cancer (HCC) without Macrovascular Invasion. Eur. J. Cancer. 2020;134:41.